Cipla partners with Hetero to roll out biosimilar drug ‘Darbepoetin alfa’
Cipla, a global healthcare company which uses technology and innovation to meet every day needs of all patients announced a […]
Say something
Tags: biology, Biosimilar, biosimilar product, biosimilar products, blood transfusions, Business Partnership, Chief Medical Officer, China, chronic kidney disease, Cipla, CIPLA LIMITED, darbepoetin alfa, Dialysis, Erythropoiesis-stimulating agents, Erythropoietin, Health/Medical/Pharmaceuticals, healthcare, India, Jaideep Gogtay, medicine, Pharmacology, renal replacement therapy, renal transplant, Rs, treatment for anaemia associated with chronic kidney disease
-
-
Flipkart Health+ App Launched
06-04-2022
